Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CFTR antisense RNA 2 (CFTR-AS2) is a long non-coding RNA transcribed from the CFTR gene locus, running antisense to the coding direction of CFTR. It is thought to play a regulatory role in CFTR gene expression, potentially affecting mRNA processing, stability, and degradation. CFTR-AS2 is being studied for its relevance in cystic fibrosis pathology, particularly as an RNA-based target for therapies aiming to restore or modulate CFTR protein production in patients with nonsense or splicing mutations. Although direct therapeutic targeting of CFTR-AS2 has not yet reached the clinic, its regulatory functions may inform future RNA-based therapies for cystic fibrosis.
Not applicable for drugs directly targeting CFTR-AS2; ASOs modulate splicing, stability, or translation of CFTR mRNA, potentially indirectly involving CFTR-AS2
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CFTR antisense RNA 2 (CFTR-AS2).